Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of FAK kinase activity preferentially targets cancer stem cells.
Kolev VN, Tam WF, Wright QG, McDermott SP, Vidal CM, Shapiro IM, Xu Q, Wicha MS, Pachter JA, Weaver DT. Kolev VN, et al. Among authors: weaver dt. Oncotarget. 2017 Jun 16;8(31):51733-51747. doi: 10.18632/oncotarget.18517. eCollection 2017 Aug 1. Oncotarget. 2017. PMID: 28881682 Free PMC article.
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI, Xu Q, Testa JR, Pachter JA. Shapiro IM, et al. Among authors: weaver dt. Sci Transl Med. 2014 May 21;6(237):237ra68. doi: 10.1126/scitranslmed.3008639. Sci Transl Med. 2014. PMID: 24848258 Free PMC article.
PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.
Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, Ricono J, Weaver DT, Padval MV, Pachter JA, Xu Q. Kolev VN, et al. Among authors: weaver dt. Cancer Res. 2015 Jan 15;75(2):446-55. doi: 10.1158/0008-5472.CAN-14-1223. Epub 2014 Nov 28. Cancer Res. 2015. PMID: 25432176
Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.
Churchman ML, Evans K, Richmond J, Robbins A, Jones L, Shapiro IM, Pachter JA, Weaver DT, Houghton PJ, Smith MA, Lock RB, Mullighan CG. Churchman ML, et al. Among authors: weaver dt. JCI Insight. 2016;1(4):e86082. doi: 10.1172/jci.insight.86082. Epub 2016 Apr 7. JCI Insight. 2016. PMID: 27123491 Free PMC article.
Focal Adhesion Kinase as a Potential Target in AML and MDS.
Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M. Carter BZ, et al. Among authors: weaver dt. Mol Cancer Ther. 2017 Jun;16(6):1133-1144. doi: 10.1158/1535-7163.MCT-16-0719. Epub 2017 Mar 7. Mol Cancer Ther. 2017. PMID: 28270436 Free PMC article.
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
Begum A, Ewachiw T, Jung C, Huang A, Norberg KJ, Marchionni L, McMillan R, Penchev V, Rajeshkumar NV, Maitra A, Wood L, Wang C, Wolfgang C, DeJesus-Acosta A, Laheru D, Shapiro IM, Padval M, Pachter JA, Weaver DT, Rasheed ZA, Matsui W. Begum A, et al. Among authors: weaver dt. PLoS One. 2017 Jul 10;12(7):e0180181. doi: 10.1371/journal.pone.0180181. eCollection 2017. PLoS One. 2017. PMID: 28692661 Free PMC article.
PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.
Muz B, Buggio M, Azab F, de la Puente P, Fiala M, Padval MV, Weaver DT, Pachter JA, Vij R, Azab AK. Muz B, et al. Among authors: weaver dt. Haematologica. 2019 Jul;104(7):e310-e313. doi: 10.3324/haematol.2018.194688. Epub 2019 Jan 17. Haematologica. 2019. PMID: 30655367 Free PMC article. No abstract available.
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedrés S, Nolan L, Kindler H, Aerts JGJV. Fennell DA, et al. Among authors: weaver dt. J Clin Oncol. 2019 Apr 1;37(10):790-798. doi: 10.1200/JCO.2018.79.0543. Epub 2019 Feb 20. J Clin Oncol. 2019. PMID: 30785827 Clinical Trial.
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.
Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, Bean LM, Sulzmaier FJ, Jean C, Tancioni I, Anderson K, Uryu S, Cordasco EA, Li J, Chen XL, Fu G, Ojalill M, Rappu P, Heino J, Mark AM, Xu G, Fisch KM, Kolev VN, Weaver DT, Pachter JA, Győrffy B, McHale MT, Connolly DC, Molinolo A, Stupack DG, Schlaepfer DD. Diaz Osterman CJ, et al. Among authors: weaver dt. Elife. 2019 Sep 3;8:e47327. doi: 10.7554/eLife.47327. Elife. 2019. PMID: 31478830 Free PMC article.
126 results